Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. | ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset ...

The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...

BD has picked a new executive to lead its planned connected care segment, as the company nears the conclusion of its ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

Researchers at Johns Hopkins University have shown that an artificial intelligence-powered robot—trained on videos of ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...